Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests

被引：4

作者：

Serra Elizalde, V. ^{[1
]}

Llop-Guevara, A. ^{[1
]}

Pearson, A. ^{[2
]}

Cruz, C. ^{[1
]}

Castroviejo-Bermejo, M. ^{[1
]}

Chopra, N. ^{[2
]}

Tovey, H. ^{[3
]}

Toms, C. ^{[3
]}

Kriplani, D. ^{[2
]}

Gevensleben, H. ^{[2
]}

Roylance, R. ^{[4
]}

Chan, S. ^{[5
]}

Tutt, A. ^{[6
]}

Skene, A. ^{[7
]}

Evans, A. ^{[8
]}

Davies, H. R. ^{[9
]}

Bliss, J. ^{[10
]}

Nik-Zainal, S. ^{[11
]}

Balmana, J. ^{[12
]}

Turner, N. ^{[13
]}

机构：

[1] Vall dHebron Inst Oncol, Expt Therapeut Grp, Barcelona, Spain

[2] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England

[3] Inst Canc Res, Clin Trials & Stat Unit, London, England

[4] UCLH Univ Coll London Hosp NHS Fdn Trust, Oncol, London, England

[5] Nottingham Univ Hosp Trust, City Campus, Nottingham, England

[6] Kings Coll London, Guys Hosp, Breast Canc Now Res Unit, Ctr Canc, London, England

[7] Royal Bournemouth Hosp, Surg, Bournemouth, Dorset, England

[8] Poole Hosp NHS Fdn Trust, Surg, Poole, Dorset, England

[9] Univ Cambridge, MRC Canc Unit, Cambridge, England

[10] ICR Inst Canc Res, Clin Trials & Stat Unit, London, England

[11] Addenbrookes Treatment Ctr, Dept Med Genet, Cambridge, England

[12] Vall dHebron Inst Oncol, Oncol, Barcelona, Spain

[13] Royal Marsden Hosp NHS Fdn Trust, Breast Unit, London, England

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

基金：

英国惠康基金;

关键词：

D O I：

10.1016/j.annonc.2021.03.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

下载

页码：S21 / S22

页数：2

共 24 条

[1] Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
Llop-Guevara, A.
Loibl, S.
Villacampa, G.
Vladimirova, V.
Schneeweiss, A.
Karn, T.
Zahm, D. -m.
Herencia-Ropero, A.
Jank, P.
van Mackelenbergh, M.
Fasching, P. A.
Marme, F.
Stickeler, E.
Schem, C.
Dienstmann, R.
Florian, S.
Nekljudova, V.
Balmana, J.
Hahnen, E.
Denkert, C.
Serra, V.
ANNALS OF ONCOLOGY, 2021, 32 (12) : 1590 - 1596
[2] Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial
Llop-Guevara, A.
Vladimirova, V.
Schneeweiss, A.
Villacampa, G.
Karn, T.
Zahm, D-M.
Herencia-Ropero, A.
Jank, P.
van Mackelenbergh, M.
Fasching, P. A.
Marme, F.
Stickeler, E.
Schem, C.
Dienstmann, R.
Florian, S.
Nekljudova, V.
Balmana, J.
Denkert, C.
Loibl, S.
Serra, V.
ANNALS OF ONCOLOGY, 2021, 32 : S22 - S22
[3] Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
Cardillo, Thomas M.
Mostafa, Ali A.
Rossi, Diane L.
Liu, Donglin
Chang, Chien-Hsing
Sharkey, Robert M.
Goldenberg, David M.
CANCER RESEARCH, 2017, 77
[4] Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency
Liao, Gaoming
Yang, Yiran
Xie, Aimin
Jiang, Zedong
Liao, Jianlong
Yan, Min
Zhou, Yao
Zhu, Jiali
Hu, Jing
Zhang, Yunpeng
Xiao, Yun
Li, Xia
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
[5] RECAP (REpair CAPacity) identifies a subset of breast cancers unable to form RAD51 foci which are undetected by DNA-based BRCAness tests
Meijer, Titia G.
Nguyen, Luan
van Hoeck, Arne
Ladan, Marjolijn M.
Verkaik, Nicole S.
Ruigrok-Ritstier, Kirsten
van Deurzen, Carolien H.
van de Werken, Harmen J.
Lips, Esther H.
Linn, Sabine C.
Memari, Yasin
Davies, Helen
Nik-Zainal, Serena
Kanaar, Roland
Martens, John W.
Cuppen, Edwin
Jager, Agnes
van Gent, Dik C.
CANCER RESEARCH, 2022, 82 (12)
[6] Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer
Wang, Zheng
Lu, Yujie
Han, Mengyuan
Li, Anqi
Ruan, Miao
Tong, Yiwei
Yang, Cuiyan
Zhang, Xiaotian
Zhu, Changbin
Wang, Chaofu
Shen, Kunwei
Dong, Lei
Chen, Xiaosong
BREAST CANCER RESEARCH AND TREATMENT, 2024, : 429 - 440
[7] Impact of homologous recombination deficiency (HRD) biomarkers on outcomes in triple-negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313)
Sharma, Priyanka
Barlow, William
Godwin, Andrew K.
Pathak, Harsh
Isakova, Kamilla
Hartman, Anne R.
Timms, Kristen M.
Linden, Hannah M.
Tripathy, Debu
Hortobagyi, Gabriel N.
Hayes, Daniel F.
CANCER RESEARCH, 2017, 77
[8] Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
Galland, Loick
Roussot, Nicolas
Desmoulins, Isabelle
Mayeur, Didier
Kaderbhai, Coureche
Ilie, Silvia
Hennequin, Audrey
Reda, Manon
Albuisson, Juliette
Arnould, Laurent
Boidot, Romain
Truntzer, Caroline
Ghiringhelli, Francois
Ladoire, Sylvain
CANCERS, 2023, 15 (04)
[9] Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis
Telli, M. L.
McMillan, A.
Ford, J. M.
Richardson, A. L.
Silver, D. P.
Isakoff, S. J.
Kaklamani, V. G.
Gradishar, W.
Stearns, V.
Connolly, R. M.
Loibl, S.
Elkin, E. P.
Timms, K.
Hartman, A-R
von Minckwitz, G.
CANCER RESEARCH, 2016, 76
[10] Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis
Telli, M. L.
McMillan, A.
Ford, J. M.
Richardson, A. L.
Silver, D. P.
Isakoff, S. J.
Kaklamani, V. G.
Gradishar, W.
Stearns, V.
Connolly, R. M.
Loibl, S.
Elkin, E. P.
Timms, K.
Hartman, A-R
von Minckwitz, G.
CANCER RESEARCH, 2016, 76

← 1 2 3 →